20 citations
,
September 2022 in “Journal of Biomedical Optics” PBM helps improve cell survival in 3D tissue engineering.
2 citations
,
December 2015 in “Journal of dermatology” β-interferon injections for melanoma can cause excessive hair growth at the injection sites.
18 citations
,
December 2010 in “Transplantation Proceedings” Black hairy tongue can be an early sign of graft-versus-host disease after stem cell transplants.
A new method improves betulin delivery in experiments, showing promise against certain tumors.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.
Telogen Effluvium causes increased hair shedding and can be challenging to diagnose and treat.
May 2025 in “The Journal of Rheumatology” Trans-esophageal echocardiography is crucial for accurately diagnosing heart issues in lupus patients.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
October 2024 in “Journal of the Endocrine Society” Type B Insulin Resistance Syndrome is rare, linked to lupus, and hard to treat due to severe insulin resistance.
26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
11 citations
,
May 2008 in “British journal of dermatology/British journal of dermatology, Supplement” Identical p53 gene mutations in different cancers suggest the need for careful treatment.
March 2026 in “Voprosy dermatologii i venerologii/Dermatologiâ ža̋ne veneralogiâ ma̋selelerì” Early diagnosis, genetic testing, and personalized care are essential for managing tuberous sclerosis.
27 citations
,
March 2019 in “PLoS ONE” Thyroxine (T4) may help heal skin wounds by promoting new skin and blood vessel growth.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology”
December 2024 in “Medical alphabet” Understanding and addressing the causes of telogen effluvium is crucial for effective treatment.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
June 2026 in “Research Square” THBS4 helps hair grow by activating hair follicle stem cells.
February 2006 in “Inpharma Weekly”
July 2018 in “Elsevier eBooks” Telogen Effluvium is a common, usually reversible hair loss condition, often improved by removing the trigger and possibly treated with various products, though their effectiveness is uncertain.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
January 2026 in “International Journal of Advanced Biochemistry Research” The dog improved significantly after treatment and needs lifelong thyroid medication.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
15 citations
,
June 2015 in “PLoS ONE” Thymosin beta-4 promotes hair growth in mice.
13 citations
,
January 2021 in “Journal of Cellular and Molecular Medicine” Thymosin β4 may boost hair growth by aiding stem cell movement and blood vessel formation.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
July 2024 in “Journal of Investigative Dermatology” Recombinant human TSG-6 speeds up wound healing in diabetic mice.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
12 citations
,
May 2016 in “British Journal of Dermatology” A 6-year-old boy's skin condition improved after stopping a specific treatment and starting new medications.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.